GP financing, explained. How managers borrow against fees and carry, and why it is so hard to find below $30m

GP financing is a loan or preferred instrument provided at the manager level, to the general partner, the management company or a sponsor affiliate, rather than to the fund. It is secured on what those entities and their owners actually hold, which means equity in the management company, the right to receive management fees, funded interests in prior funds and the entitlement to carried interest, and those cash flows are the expected source of repayment. No fund property and no LP commitment is pledged, and in most structures the underlying portfolio companies never know the facility exists.

That is the definition. What follows is how it works, what lenders take as security, why banks find it awkward, and why standalone GP financing below about $30m is so thin. I run a lender in that gap, so read the last section with that in mind.

What GPs use it for

Five uses account for nearly everything we see. The first is the GP commitment to a new fund. Institutional LPs generally look for 2% to 5% from the manager, and on a $500m raise that is $10m to $25m the partners must fund as it is called, often while their prior funds are distributing slowly. The second is bridging capital calls and co-investment obligations that land before carry or fees arrive. The third is management company growth, the hiring and systems that fee income will pay for but not on the plan's timetable. The fourth is succession, a founder buying out a retiring partner without selling a stake to an outsider to do it. The fifth is advancing a conservative portion of accrued carry, where the waterfall, escrow and clawback terms allow a lender to count it.

None of these are distressed. The manager has assets and a fee stream under contract for the life of its funds, subject to the step-downs and key person terms every LPA carries. What it lacks is cash on the date it is needed. That is a timing problem, but it is still credit, and the borrower needs a repayment path that works if exits are late and carry never arrives.

What actually secures a GP loan

Lenders take the collateral in layers and a facility may lean on one or several. The management company comes first, a pledge over its equity, granted by the founders or holding vehicle that own it, plus security over its own receivables and accounts, subject to whatever consents its constitution and the fund documents require. Fee income comes second, the right to receive management fees once earned, captured through an assignment of fees, a controlled account and a reserve sized to how concentrated the fee base is, after checking who pays the fee and whether it can be redirected on enforcement. Funded interests in prior funds come third. Here a point of precision, because it gets written wrongly. What is pledged is not the uncalled commitment, which is a liability, but the sponsor's funded interests in earlier funds and the distributions they generate, after each LPA is read for restrictions on pledge, transfer and foreclosure. Carried interest is the fourth layer, where the carry vehicle's vesting, forfeiture and clawback terms permit it, taken as a security interest with a springing assignment on default. The triggers are negotiated manager by manager.

At Nodem Capital we typically write GP facilities of $10m to $100m and above, priced as a margin over SOFR or SONIA, cash pay or PIK, over two to seven years. A manager with several funds and vintages is easier to underwrite than one with a single fund, because the fee stream is longer and less lumpy, and that usually shows in the terms.

Why banks find this hard

Bank credit models want durable cash flow and hard assets. A manager's cash flow is concentrated, steps down after the investment period, and much of its value sits in unrealised positions and carry years away. When the standalone credit does not fit the box, many banks reach for the relationship instead. Three patterns follow.

The first is the relationship toll. Beyond the controlled account that any secured lender needs, some banks make the loan conditional on the manager moving operating accounts, deposits and custody across. If you are happy where you bank, that conversation is short.

The second is quieter and, in my view, worse. The GP loan is offered as part of a package in which the fund takes its subscription line from the same bank. Even where the fund facility is properly authorised and priced, the GP now has to show its LPAC that fund-level terms were set at arm's length and not shaped by the manager's own need for money. That is an awkward conversation, and it is why we structure GP facilities standalone, with nothing tied in at fund level.

The third is the slow yes. Credit committee approves in principle, then the ancillary negotiation and the documentation run on for months. A capital call does not wait. A yes that arrives after the deadline is a no with better manners, which is why the time to arrange a GP facility is before the obligation is dated.

Why there is almost no market below $30m

The large GP-stakes platforms are built for established managers and tickets well above $30m, and their core product is minority equity in the management company, a different product with a different answer to who owns the firm afterwards. Some of them and most specialist NAV lenders also offer manager-level debt, with minimums set for the same larger managers, and a few lower-ticket providers exist, so the market is thin rather than empty. What is left for a $15m GP commitment to a $400m fund is a short list of lenders, some family office capital and the partners' own balance sheets.

That gap is not a mystery. Much of the work on a $15m facility does not shrink because the number is small. The entity and cash flow mapping, the review of every LPA in the pool, the account control, the carry assignment. Fixed cost against a small ticket is a bad ratio for a large platform, and for the borrower's legal bill, unless the lender's process is built to absorb it, which is where we sit. From a structure chart, fund NAV statements and a summary of existing debt we aim to indicate appetite within days, issue a term sheet in about two weeks and fund in about a month, subject to diligence, KYC, documentation and any consents the fund documents require. In the situations we have been brought into, the bank process the manager started first was often already months in.

What a GP should ask any lender

What exactly do you attach to, who grants it, and does any of it reach the fund? Is anything required at fund level, a subscription line, deposits, custody, anything at all? Is recourse limited to the GP entities, or do the partners give personal guarantees? If carry is in the package, what triggers the springing assignment and who decides it has been hit? What is the all-in cost including fees and any PIK premium, and what does the balance look like at maturity if exits are late and carry is zero? A lender who answers those directly is worth an hour. One who steers back to the headline margin is telling you something.

Disclosure

Nodem Ltd, trading as Nodem Capital, is authorised and regulated by the Financial Conduct Authority (FRN 1017481) and provides NAV loans, GP financing and preferred equity to family offices and private markets managers in the US and Europe. The lending products described may fall outside the FCA's regulatory perimeter. This is a paid advertisement feature reflecting the author's views as a practitioner, not investment, legal or tax advice; terms are illustrative and any facility is subject to underwriting and documentation. A GP facility adds leverage at the manager level, accrues at a floating rate and compounds if interest is capitalised, can restrict fee and carry cash flows through sweeps, and exposes pledged interests to enforcement on default.

Advertisement feature. Alex Branton, Managing Partner, Nodem Capital.